Curis Lifesciences Ltd (CURIS) is currently trading at 218.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Curis Lifesciences Limited primarily manufactures pharmaceutical products, covering a diverse range of formulations including tablets, capsules, and ointments. Their core markets are Africa and Latin America, with a focus on contract manufacturing and direct exports. The company has a strong export focus, with 63.78% of its turnover being international, and key markets including Nigeria and Kenya. Their strategic focus on exports supports higher profit margins. Curis Lifesciences is expanding its partnerships and facilities, including a significant JV with Eurosun Pharmaceuticals for Nigerian market penetration, indicating strategic growth. The company’s contract manufacturing model provides flexibility, incorporating both domestic and international clients and catering to brand-specific needs. Curis’s recent financial performance shows robust growth in EBITDA margins, with a shift from lower-margin operations to higher-margin contract manufacturing for export markets.

Over the past 52 weeks, Curis Lifesciences Ltd has traded between a low of ₹83.60 and a high of ₹218.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Curis Lifesciences Ltd has a market capitalization of approximately 160.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Curis Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.98 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 160.72 Cr, Curis Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Curis Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Curis Lifesciences Ltd is 29.98. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.